A PSEN1 genetic test checks for disease-causing changes in the PSEN1 gene that cause early-onset Alzheimer disease. It is highly accurate at reading DNA, but it cannot predict exact onset or rule out all dementia, it often costs $1,000-$2,000 or more, and it calls for counseling and neurologic follow-up. PSEN1 means presenilin 1, a gene on chromosome 14 that controls amyloid processing in the brain. Pathogenic variants are the most common cause of autosomal-dominant early-onset Alzheimer disease, with complete or near-complete penetrance and typical symptom onset at ages 30-60.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does the test check?
- How accurate is the result?
- What are the main limits?
- How much does it cost and what should you do next?
What does the test check?
Clinical PSEN1 testing uses next-generation sequencing plus deletion and duplication analysis. It is usually ordered as a three-gene early-onset panel with APP and PSEN2, using blood, saliva, or extracted DNA. The American College of Medical Genetics and NSGC joint guidelines describe PSEN1 on chromosome 14 as the most common cause of autosomal-dominant early-onset Alzheimer disease (joint guidelines).
An Alzheimer's and Dementia review reports more than 300 PSEN1 variants, accounting for roughly 50-75% of familial early-onset cases and about 6% of all early-onset cases (2021 review). Doctors usually reserve this panel for families with early memory loss, multiple relatives affected before age 60, or a known PSEN1 variant. It is not general dementia screening.
How accurate is the result?
Laboratory reading accuracy is very high. Analytic sensitivity of next-generation sequencing exceeds 99%. Clinical detection is lower because many families have a different genetic or unknown cause.
Regence medical policy estimates PSEN1 sequencing finds a causative variant in 30-60% of familial early-onset Alzheimer families (Regence medical policy). A positive result for a known pathogenic variant strongly supports inherited early-onset Alzheimer risk. A negative result lowers concern for PSEN1 but does not remove the chance of another cause.
What are the main limits?
A negative PSEN1 result does not exclude dementia. Other genes, non-inherited Alzheimer disease, and other brain disorders can still cause symptoms. Results can also be complex inside families.
The same variant can show variable expression among relatives, and testing can return a variant of uncertain significance that needs expert interpretation. Even with a positive result, testing cannot reliably predict exact onset age, symptom type, severity, or rate of progression in an asymptomatic at-risk adult. Families should treat the result as risk information, not a personal timeline.
How much does it cost and what should you do next?
Medscape reports out-of-pocket Alzheimer gene-test costs commonly cited at $1,000-$2,000 or more plus counseling, with coverage generally limited to symptomatic or high-risk familial cases rather than general screening (Medscape report). Confirm price, laboratory, panel contents, and insurance rules before testing. The Alzheimer's Association genetics page points to pre- and post-test genetic counseling, neurologic evaluation, testing an affected relative first when possible, and referral through the National Society of Genetic Counselors.
Counseling helps weigh family planning, work leave, care plans, and emotional effects. U.S. GINA protection bars health-insurer and employment discrimination based on genetic results but does not cover life, disability, or long-term-care insurance. That gap matters because Alzheimer results can affect future applications for those policies.
- Ask a neurologist whether an early-onset Alzheimer panel fits your family history
- Meet a genetic counselor before testing to review benefits, limits, and insurance effects
- Test an affected relative first when possible to make results clearer
- Plan result disclosure, follow-up care, and support for relatives





